N Engl J Med 358:25602572 Anandhakrishnan A, Korbonits M (2016) Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Major Reclassification : This detailed, stepwise procedure applies to applications that break new ground, such as a new type of medicine or condition being considered for a classification change
Choose Saxenda if: You prefer daily dosing, want FDA-approved weight loss medication with an established safety record, didnt respond well to semaglutide, or prefer a shorter-acting medication
doi: 10.1080/02688697.2020.1861433 7 IzzedineHBrocheriouIArzoukNSeilheanDCouvertPCluzelPet al
Thats because you get the power of the medicine plus expert help to make it work better
43: 146977 De Grandis D, Santoro L, Di Benedetto P